Lexeo Therapeutics, Inc. (LXEO)
NASDAQ: LXEO · Real-Time Price · USD
6.12
+0.10 (1.66%)
At close: Nov 20, 2024, 4:00 PM
6.42
+0.30 (4.90%)
After-hours: Nov 20, 2024, 6:40 PM EST
Lexeo Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Lexeo Therapeutics stock have an average target of 22.71, with a low estimate of 19 and a high estimate of 28. The average target predicts an increase of 271.08% from the current stock price of 6.12.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for LXEO stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $21 → $23 | Strong Buy | Maintains | $21 → $23 | +275.82% | Nov 14, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $23 → $25 | Strong Buy | Maintains | $23 → $25 | +308.50% | Nov 13, 2024 |
| Leerink Partners | Leerink Partners | Buy Maintains $20 → $19 | Buy | Maintains | $20 → $19 | +210.46% | Nov 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $21 | Strong Buy | Reiterates | $21 | +243.14% | Oct 31, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $23 | Strong Buy | Maintains | $23 | +275.82% | Oct 30, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
655.72K
EPS This Year
-2.82
from -12.40
EPS Next Year
-2.82
from -2.82
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | 4.7M | n/a | ||
| Avg | n/a | 655,717 | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.68 | -1.90 | -1.67 | ||
| Avg | -2.82 | -2.82 | -2.90 | ||
| Low | -2.95 | -3.76 | -4.43 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.